Related Experiment Videos
Clearing amyloid through the blood-brain barrier
1Frank P. Smith Laboratories for Neuroscience, Department of Neurological Surgery, University of Rochester Medical Center, New York 14642, USA. berislav_zlokovic@urmc.rochester.edu
Journal of Neurochemistry
|May 14, 2004
Summary
Alzheimer's disease may be treated by targeting amyloid beta-peptide (A beta) transport between the brain and blood. Understanding these exchanges offers new therapeutic strategies for Alzheimer's disease.
Area of Science:
- Neuroscience
- Pathology
- Pharmacology
Background:
- The amyloid hypothesis posits that amyloid beta-peptide (A beta) accumulation drives Alzheimer's disease (AD) pathogenesis.
- Emerging evidence links A beta in the bloodstream to brain A beta deposits.
- A beta transport across the blood-brain barrier and between the brain, blood, and cerebrospinal fluid is crucial for regulating brain A beta levels.
Purpose of the Study:
- To investigate the role of A beta transport in Alzheimer's disease.
- To explore the potential of systemic A beta-lowering strategies based on transport mechanisms.
Main Methods:
- This study focuses on the theoretical and evidential basis of A beta transport mechanisms.
- It reviews existing literature on A beta exchange between the central nervous system and peripheral circulation.
Main Results:
- A beta transport across the blood-brain barrier is a key regulator of brain A beta burden.
- Interventions targeting systemic A beta levels may influence brain pathology.
Conclusions:
- Understanding A beta exchange dynamics between the brain and blood is critical for AD pathogenesis.
- Transport-based strategies targeting systemic A beta reduction represent a promising therapeutic avenue for Alzheimer's disease.